drugset / Trial / NCT00660257
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
Phase 1
Completed
57 enrolled
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China · collab
Non-randomizedParallel-groupDouble-blindPrevention
Summary
A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1) vaccine (whole-virion, aluminium-adjuvanted).
Timeline
- Start
- 2007-01
- Primary completion
- 2007-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 1.25 ug | Intramuscular |
| Subject | pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 2.5 ug | Intramuscular |
| Subject | pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 5 ug | Intramuscular |
| Subject | pandemic influenza vaccine (H5N1 strain NIBRG-14) | Vaccine | 10 ug | Intramuscular |